• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cantargia

2.15 SEK

+0.56 %

1,288 following

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.56 %
-29.31 %
-48.54 %
-48.72 %
-47.59 %
+70.59 %
-50.98 %
-89.75 %
-69.63 %

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Read more
Market cap
605.05M SEK
Turnover
965.34K SEK
Revenue
316.7M
EBIT %
48.66 %
P/E
3.64
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.8
2026

Interim report Q2'26

25.11
2026

Interim report Q3'26

24.2
2027

Annual report '26

Press release26.06.2026, 07.30

Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC

Cantargia
Regulatory press release23.06.2026, 20.30

Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital

Cantargia
Press release11.06.2026, 07.30

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

Cantargia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10.06.2026, 07.30

Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study

Cantargia
Regulatory press release05.06.2026, 08.15

Cantargia publishes Information Document regarding Rights Issue of Shares

Cantargia
Cantargia AB, Press Conference
Webcast01.06.2026, 16.00

Cantargia AB, Press Conference

Cantargia
Press release28.05.2026, 21.20

Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities

Cantargia
Regulatory press release28.05.2026, 21.15

Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million

Cantargia
Regulatory press release21.05.2026, 16.00

Bulletin from the Annual General Meeting in Cantargia AB (publ)

Cantargia
Press release21.05.2026, 11.57

Redeye: Cantargia (Q1 Review): Shift Towards RAS Combination Strategy

Cantargia
Cantargia, Audiocast, Q1'26
Webcast19.05.2026, 15.00

Cantargia, Audiocast, Q1'26

Cantargia
Regulatory press release19.05.2026, 07.00

Cantargia publishes interim report for the first quarter of 2026

Cantargia
Press release06.05.2026, 10.00

Invitation to the Presentation of Cantargia’s Interim Report for Q1 2026

Cantargia
Press release27.04.2026, 07.00

Cantargia Announces Early Results from Trial of nadunolimab in MDS and AML

Cantargia
Press release17.04.2026, 21.00

Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC

Cantargia
Regulatory press release17.04.2026, 07.31

Cantargia publishes Annual Report 2025

Cantargia
Regulatory press release17.04.2026, 07.30

Notice of annual general meeting in Cantargia AB (publ)

Cantargia
Press release18.03.2026, 07.30

New preclinical data on anti-tumor effects of nadunolimab in metastatic colorectal cancer presented at the Keystone Cancer Immunotherapy conference

Cantargia
Press release05.03.2026, 10.00

Cantargia to participate at Van Lanschot Kempen’s Life Sciences Conference

Cantargia
Press release24.02.2026, 10.30

Redeye: Cantargia (Q4 Review): New Developments in PDAC

Cantargia